ARTICLES BY JOHN CARLOS DIAZ
-
![Handshake]( "5 Keys To Establishing Quality Partnerships Between Sponsors And CROs")
5 Keys To Establishing Quality Partnerships Between Sponsors And CROs3/13/2018What is the cost of a failed partnership between a pharma company and its CROs? Is it financial? Research and development time?
-
![Business conflict]( "Tips For Improving Communication Between Sponsors And CROs")
Tips For Improving Communication Between Sponsors And CROs12/21/2017Clinical research is incredibly complex, and most pharma/biotech companies outsource a lot of the trial oversight responsibilities to contract research organizations (CROs). The increasingly level of complexity and global nature of clinical research has led to poor communication within pharma and between sponsors and their CROs.
-
![time market graph business 450x300]( "Does The First-Patient-In Milestone Really Matter?")
Does The First-Patient-In Milestone Really Matter?11/16/2017Sorry, pharma executives. We have all been duped for years that the FPI milestone yields an increase in stock price and company value.
John Carlos Diaz
John Carlos Diaz has been in the pharmaceutical industry for 18 years, with ranging operational experiences from preclinical drug metabolism and pharmacokinetics (DPMK), clinical pharmacology/Phase 1, adult/pediatric, global Phase 2–4, and investigator-initiated trials. Currently, John and GeoSera are using their experienced clinical research network to benefit sponsor companies, clinical research sites, clinical trial service providers, and CROs. You can reach him at johndiaz@geosera.com or 484-568-3952.